Metabolic syndrome and its components are associated with non-arteritic anterior ischaemic optic neuropathy.
Optic Nerve
Journal
BMJ open ophthalmology
ISSN: 2397-3269
Titre abrégé: BMJ Open Ophthalmol
Pays: England
ID NLM: 101714806
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
06
07
2022
accepted:
13
08
2022
entrez:
28
11
2022
pubmed:
29
11
2022
medline:
30
11
2022
Statut:
ppublish
Résumé
To determine whether metabolic syndrome (MetS) is a risk factor for various forms of optic neuropathy including non-arteritic anterior ischaemic optic neuropathy (NAION). This population-based analysis identified patients ≥40 years of age in Olmsted County, Minnesota, USA using the Rochester Epidemiology Project 2005-2018. Patients with MetS were identified if three or more of the five standard criteria for diagnosing MetS were present: systemic hypertension, hyperglycaemia, hypertriglyceridaemia, reduced high-density lipoprotein cholesterol (hypoalphalipoproteinaemia) and central adiposity defined by increased body mass index. Charts of patients identified as having an optic neuropathy were reviewed to record specific diagnoses and compared with patients without ocular pathology other than cataract. The odds ratio (OR) of association with MetS was calculated and adjusted for age, sex and race with multivariate analysis for the various optic neuropathies. Patients with MetS were more likely to have an optic neuropathy than those without (OR 2.2, p<0.001). After adjusting for age, sex and race, the only optic neuropathy found to be significantly associated with MetS was NAION (OR 6.17, p=0.002). For patients with NAION, though each individual component of MetS was individually significantly associated with MetS, further analysis suggested that hypertriglyceridaemia, hypoalphalipoproteinaemia and hyperglycaemia were likely the key drivers in the overall significance between NAION and MetS. Patients with MetS were more likely to have NAION. Further studies are needed to determine whether MetS is a modifiable risk factor for NAION.
Identifiants
pubmed: 36437528
pii: bmjophth-2022-001111
doi: 10.1136/bmjophth-2022-001111
pmc: PMC9535188
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIA NIH HHS
ID : R33 AG058738
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Acta Ophthalmol. 2017 Nov;95(7):e564-e574
pubmed: 28677865
N Engl J Med. 2019 Dec 19;381(25):2440-2450
pubmed: 31851800
Annu Rev Immunol. 2011;29:415-45
pubmed: 21219177
Arq Bras Oftalmol. 2008 Jan-Feb;71(1):62-6
pubmed: 18408840
Prog Retin Eye Res. 2009 Jan;28(1):34-62
pubmed: 19063989
Curr Opin Lipidol. 2019 Oct;30(5):364-369
pubmed: 31348023
Front Med (Lausanne). 2021 Oct 04;8:618353
pubmed: 34671609
Neuroophthalmology. 2017 Jan 11;41(2):68-75
pubmed: 28348628
Lancet. 2005 Apr 16-22;365(9468):1415-28
pubmed: 15836891
Br J Ophthalmol. 2019 Aug;103(8):1123-1128
pubmed: 30413419
Clin Biochem. 2021 Mar;89:63-69
pubmed: 33333061
Curr Hypertens Rep. 2018 Feb 26;20(2):12
pubmed: 29480368
J Am Coll Cardiol. 2010 Sep 28;56(14):1113-32
pubmed: 20863953
Endocrinol Metab Clin North Am. 2014 Mar;43(1):1-23
pubmed: 24582089
Int J Ophthalmol. 2011;4(3):272-4
pubmed: 22553660
J Glaucoma. 2022 Jun 1;31(6):e18-e31
pubmed: 34860182
Diabetes Res Clin Pract. 2016 Mar;113:86-100
pubmed: 26838669
Curr Cardiol Rep. 2013 Sep;15(9):400
pubmed: 23881582
Nature. 2006 Dec 14;444(7121):881-7
pubmed: 17167477
Mayo Clin Proc. 2012 Dec;87(12):1202-13
pubmed: 23199802
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Ophthalmology. 1999 Apr;106(4):739-42
pubmed: 10201595
Int J Ophthalmol. 2021 Jul 18;14(7):1041-1046
pubmed: 34282389
Sci Rep. 2016 Dec 22;6:38283
pubmed: 28004731
Med J Islam Repub Iran. 2015 Nov 22;29:300
pubmed: 26913263
BMC Public Health. 2010 Sep 02;10:529
pubmed: 20813031
Curr Opin Ophthalmol. 2021 May 1;32(3):280-287
pubmed: 33630786
J Clin Hypertens (Greenwich). 2005 Feb;7(2):130-3
pubmed: 15722660
Free Radic Biol Med. 2002 Oct 15;33(8):1026-36
pubmed: 12374614
Dis Model Mech. 2009 May-Jun;2(5-6):231-7
pubmed: 19407331
PLoS One. 2014 Nov 07;9(11):e112450
pubmed: 25380250
JAMA. 2015 May 19;313(19):1973-4
pubmed: 25988468
PLoS One. 2013 Sep 30;8(9):e76653
pubmed: 24098798
Eur J Public Health. 2015 Apr;25(2):255-62
pubmed: 25320051
Cell Metab. 2018 Jun 05;27(6):1176-1199
pubmed: 29874566
Ophthalmology. 2016 Dec;123(12):2446-2455
pubmed: 27659545
Hamostaseologie. 2016;36(1):46-54
pubmed: 26778257
Am J Ophthalmol. 2022 Oct;242:156-164
pubmed: 35764105
Open Ophthalmol J. 2015 Oct 06;9:149-55
pubmed: 26535072
J Glaucoma. 2020 Sep;29(9):726-731
pubmed: 32618805
Eye Brain. 2017 Sep 27;9:23-28
pubmed: 29033621
Semin Immunopathol. 2018 Feb;40(2):215-224
pubmed: 29209827
Diabetes Metab J. 2020 Jun;44(3):414-425
pubmed: 31950773
Curr Eye Res. 2020 Jun;45(6):726-732
pubmed: 31735070
Ophthalmology. 2003 May;110(5):1041-6; discussion 1046
pubmed: 12750110
Vasc Endovascular Surg. 2016 Feb;50(2):107-18
pubmed: 26983667